Eloxx reports Q3 net loss of $9.9M; Phase 2 CF data on track for Q4 2021

Eloxx Pharmaceuticals, Inc.

2022-Q3 EPS reported -$0.85

Net loss of $9.9M ($0.11/share) vs $6.6M loss; R&D spending rose to $5.2M.
Cash $52.4M as of Sep 30, 2021; expected to fund operations into Q1 2023.
Entered debt facility with Hercules Capital for up to $30M, initial draw $12.5M.
Appointed Dr. Ali Hariri as Chief Medical Officer.
FDA Fast Track designation for ELX-02; Phase 2 monotherapy data expected Q4 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.